Navigating Regulatory and Reimbursement Disruption: How Accelerated Approvals and Pricing Reforms Are Reshaping Pharmaceutical Royalty Valuations
Introduction: The Perfect Storm of Regulatory and Pricing Uncertainty
The pharmaceutical royalty market is experiencing an unprecedented convergence of regulatory and reimbursement disruptions that fundamentally challenge traditional valuation methodologies. For royalty investors who purchase rights to future drug revenues, the landscape has shifted from predictable, linear risk models to a